Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Accumulated Expenses (2020 - 2023)

Historic Accumulated Expenses for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $3.4 million.

  • Candel Therapeutics' Accumulated Expenses fell 2285.71% to $3.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $3.4 million, marking a year-over-year decrease of 2285.71%. This contributed to the annual value of $4.7 million for FY2022, which is 3737.64% up from last year.
  • According to the latest figures from Q3 2023, Candel Therapeutics' Accumulated Expenses is $3.4 million, which was down 2285.71% from $3.5 million recorded in Q2 2023.
  • Candel Therapeutics' Accumulated Expenses' 5-year high stood at $4.7 million during Q4 2022, with a 5-year trough of $2.9 million in Q1 2023.
  • Moreover, its 4-year median value for Accumulated Expenses was $3.5 million (2023), whereas its average is $3.6 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 3737.64% in 2022, then tumbled by 2285.71% in 2023.
  • Over the past 4 years, Candel Therapeutics' Accumulated Expenses (Quarter) stood at $3.1 million in 2020, then rose by 9.42% to $3.4 million in 2021, then soared by 37.38% to $4.7 million in 2022, then decreased by 27.4% to $3.4 million in 2023.
  • Its Accumulated Expenses stands at $3.4 million for Q3 2023, versus $3.5 million for Q2 2023 and $2.9 million for Q1 2023.